{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of August 2023): No"],"condition":["Colorectal cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/90532"],"location":["China"],"study_start_month":["5"],"keyword":["Fruquintinib"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study","description":"The overall 5-year survival rate for patients with colorectal liver metastases (CRLM) is still less than 20%. Surgery-based local treatment can achieve no evidence of disease (NED) in CRLM patients, but over 60% of patients experience recurrence even after achieving NED. Even with adjuvant therapy for the 6-month perioperative period after achieving NED, the recurrence rate remains high. Fruquintinib is a selective anti-angiogenic inhibitor that may help reduce tumor recurrence and prolong the time to recurrence and metastasis. The Chinese Society of Clinical Oncology (CSCO) guidelines have recommended fruquintinib as a third-line therapy for colorectal cancer. This study aims to evaluate the effectiveness and safety of fruquintinib as a maintenance therapy for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy.","dates":{"creation":"2023-05-15"},"accession":"90532","cross_references":{"ClinicalTrials___gov":["NCT06018714"]}}